First big depression advance since Prozac nears FDA approval
February 14, 2019

From Bloomberg:

The U.S. Food and Drug Administration is on the brink of approving a breakthrough drug that could upend the way severe depression is treated.

Johnson & Johnson's esketamine, a close chemical cousin of the anesthetic ketamine, cleared a major hurdle on Tuesday when a panel of outside experts recommended that the FDA approve the treatment. The fast-acting antidepressant, administered via a nasal spray, is being tested in major depressive disorder and suicidal thinking. If approved, it would be the first major therapeutic advance for depression since the introduction of Prozac in 1987.

Prozac and other currently available antidepressants take weeks to work and don't help all patients, so esketamine could mark a significant shift in depression therapy.

Continue reading at Bloomberg...

You may also like

Two-thirds of bankruptcy filers cite illness and medical bills as contributors to financial ruin

"Researchers found no evidence that the ACA reduced the proportion of bankruptcies driven by medical problems; insurance offered little protection to middle-class Americans."

Cannabis smoking associated with higher sperm count, study finds

"Previous research involving animal experiments or men with histories of drug abuse has suggested that cannabis impairs male reproductive health."

A shockingly large majority of health news shared on Facebook is fake or misleading

"You might be surprised to learn how much false information is really out there."